DDInter1001 DDInter1435
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Ixabepilone {u} (Compound) treats {v} (Disease) breast cancer
Ixabepilone {u} (Compound) binds {v} (Gene) TUBB3
Ixabepilone {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Ixabepilone {u} (Compound) causes {v} (Side Effect) Dehydration
Ixabepilone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capecitabine
Ixabepilone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Imatinib
Ixabepilone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troleandomycin
Ixabepilone {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Ixabepilone {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Ixabepilone (Compound) treats breast cancer (Disease)
Ixabepilone (Compound) binds TUBB3 (Gene)
Ixabepilone (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Ixabepilone (Compound) causes Dehydration (Side Effect)
Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Ixabepilone may lead to a major life threatening interaction when taken with Clozapine
Ixabepilone may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated